CleanScript® method used in TriLink’s in-house mRNA manufacturing
The first critical step in mRNA manufacturing is in vitro transcription (IVT), where the mRNA molecule is synthesized. Traditional IVT methods have limitations: they require optimization for consistent yields, scalability, quality control, and minimizing dsRNA byproducts. To address these challenges in mRNA manufacturing, TriLink BioTechnologies developed its proprietary CleanScript® IVT method, a highly scalable process optimized to maximize yield and quality, enhance mRNA activity, and reduce dsRNA production.
Topics covered in this tech note include:
Challenges and limitations of the traditional IVT method
Impacts of capping technology on mRNA recovery yields
Developing a better IVT reaction: the CleanScript IVT method
Benefits of CleanScript IVT method for mRNA drug developers
Read the technical note
Please complete the form to download the tech note and learn more about how you can take advantage of the CleanScript method.
© 2024 TriLink BioTechnologies. All rights reserved. Terms | Privacy notice
